JP2019043956A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019043956A5 JP2019043956A5 JP2018210546A JP2018210546A JP2019043956A5 JP 2019043956 A5 JP2019043956 A5 JP 2019043956A5 JP 2018210546 A JP2018210546 A JP 2018210546A JP 2018210546 A JP2018210546 A JP 2018210546A JP 2019043956 A5 JP2019043956 A5 JP 2019043956A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ile
- leu
- bdnf
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940077737 Brain-Derived Neurotrophic Factor Drugs 0.000 claims 6
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 claims 6
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 claims 6
- 230000001737 promoting Effects 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 2
- 102000007544 Whey Proteins Human genes 0.000 claims 2
- 108010046377 Whey Proteins Proteins 0.000 claims 2
- 239000003531 protein hydrolysate Substances 0.000 claims 2
- 235000021119 whey protein Nutrition 0.000 claims 2
- 108010016626 Dipeptides Proteins 0.000 claims 1
- BCVIOZZGJNOEQS-XKNYDFJKSA-N Ile-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)[C@@H](C)CC BCVIOZZGJNOEQS-XKNYDFJKSA-N 0.000 claims 1
- JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical group CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 claims 1
- BCXBIONYYJCSDF-CIUDSAMLSA-N Ile-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O BCXBIONYYJCSDF-CIUDSAMLSA-N 0.000 claims 1
- AZLASBBHHSLQDB-GUBZILKMSA-N Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(C)C AZLASBBHHSLQDB-GUBZILKMSA-N 0.000 claims 1
- LCPYQJIKPJDLLB-UWVGGRQHSA-N Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C LCPYQJIKPJDLLB-UWVGGRQHSA-N 0.000 claims 1
- MDSUKZSLOATHMH-IUCAKERBSA-N Leu-Val Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C([O-])=O MDSUKZSLOATHMH-IUCAKERBSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000001771 impaired Effects 0.000 claims 1
- 108010078274 isoleucylvaline Proteins 0.000 claims 1
- 108010091798 leucylleucine Proteins 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Claims (4)
非運動状態のヒトを含む哺乳動物(運動前または運動中のヒトを含む哺乳動物を除く)に経口投与または摂取されるものである、BDNF量増加促進用組成物。 A composition for promoting an increase in the amount of brain-derived neurotrophic factor (BDNF) in the body containing a whey protein hydrolyzate as an active ingredient, and the whey protein hydrolyzate is Ile-Leu, Leu-Leu , Val-Le. u, Ile-Val, Ile- Ile, der those containing dipeptides Leu-Val, and Leu-Ile is,
Ru der those in the non-motion state in a mammal, including a human (except for mammals, including humans during exercise before or motion) are administered orally or ingested, BDNF amount increase for promoting composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017046378 | 2017-03-10 | ||
JP2017046378 | 2017-03-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018530630A Division JP6435079B1 (en) | 2017-03-10 | 2018-03-09 | Composition for promoting an increase in the amount of BDNF in the body |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019043956A JP2019043956A (en) | 2019-03-22 |
JP2019043956A5 true JP2019043956A5 (en) | 2021-04-22 |
JP7108521B2 JP7108521B2 (en) | 2022-07-28 |
Family
ID=63448663
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018530630A Active JP6435079B1 (en) | 2017-03-10 | 2018-03-09 | Composition for promoting an increase in the amount of BDNF in the body |
JP2018210546A Active JP7108521B2 (en) | 2017-03-10 | 2018-11-08 | Composition for promoting an increase in the amount of BDNF in the body |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018530630A Active JP6435079B1 (en) | 2017-03-10 | 2018-03-09 | Composition for promoting an increase in the amount of BDNF in the body |
Country Status (4)
Country | Link |
---|---|
JP (2) | JP6435079B1 (en) |
CN (1) | CN110381965A (en) |
TW (1) | TWI773739B (en) |
WO (1) | WO2018164254A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7011984B2 (en) * | 2018-07-13 | 2022-01-27 | キリンホールディングス株式会社 | Composition for improving attention function and judgment function |
JP2020058346A (en) * | 2018-10-05 | 2020-04-16 | 公立大学法人名古屋市立大学 | Composition for improving cognitive function |
JP2020176100A (en) * | 2019-04-22 | 2020-10-29 | 株式会社明治 | Compositions for suppressing exercise-induced muscle damage |
WO2020239998A1 (en) * | 2019-05-29 | 2020-12-03 | Arla Foods Amba | Palatable extensively hydrolysed whey protein hydrolysates |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2039366A4 (en) * | 2006-04-21 | 2010-01-06 | Meiji Seika Kaisha | Composition containing peptide as the active ingredient |
MX2016007630A (en) * | 2013-12-13 | 2016-09-09 | Nestec Sa | Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions. |
BR112016027871A2 (en) * | 2014-06-16 | 2017-10-24 | Kirin Kk | composition to improve memory, learning function and / or cognitive function |
JPWO2017026429A1 (en) * | 2015-08-10 | 2018-05-31 | 株式会社明治 | Muscle synthesis promoter |
-
2018
- 2018-03-09 WO PCT/JP2018/009138 patent/WO2018164254A1/en active Application Filing
- 2018-03-09 CN CN201880016219.7A patent/CN110381965A/en active Pending
- 2018-03-09 JP JP2018530630A patent/JP6435079B1/en active Active
- 2018-03-09 TW TW107108071A patent/TWI773739B/en active
- 2018-11-08 JP JP2018210546A patent/JP7108521B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019043956A5 (en) | ||
Budhiraja et al. | Sleep-disordered breathing and cardiovascular disorders | |
JP2018193377A5 (en) | ||
JP2018012722A5 (en) | ||
JP2014530874A5 (en) | ||
JP2017222722A5 (en) | ||
JP2014198723A5 (en) | ||
Wood | The mechanism of the increased venous pressure with exercise in congestive heart failure | |
Jakovljevic et al. | The effect of aerobic versus resistance exercise training on peak cardiac power output and physical functional capacity in patients with chronic heart failure | |
Emerson | Artificial respiration in the treatment of edema of the lungs: A suggestion based on animal experimentation | |
RU2013134133A (en) | APPLICATION OF LACTOFERRINE-CONTAINING NUTRITIONAL COMPOSITIONS IN MAINTAINING RESISTANCE TO DISEASES AND CONDITIONS | |
ATE493974T1 (en) | ORAL TEDISAMIL FORMULATIONS HAVING GASTRIC RETENTION AND SUSTAINED RELEASE PROPERTIES | |
FI3484475T3 (en) | 1-methylnicotinamide for the treatment of cardiovascular disease | |
Nose et al. | Interactions between body fluid homeostasis and thermoregulation in humans | |
JP2018199643A5 (en) | ||
JP2019156793A5 (en) | ||
Agin et al. | Effects of whey protein and resistance exercise on body composition and muscle strength in women with HIV infection | |
JP2020137724A5 (en) | ||
Turkova et al. | Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial | |
JP2015509934A5 (en) | ||
JP2017502089A5 (en) | ||
JP2006504741A5 (en) | ||
Kara et al. | Reversible sensorineural hearing loss in a girl with Kawasaki disease. | |
JP2020137722A5 (en) | ||
MA49790A (en) | DIETARY SUPPLEMENT, IN THE FORM OF A SINGLE-DOSE ORAL SOLUTION CONSISTING OF MAGNESIUM, MELATONIN, TRYPTOPHAN AND 5-HYDROXYTRYPTOPHANE, USEFUL TO REDUCE SLEEP TIME |